心臓 肥大 症: 産前 から 若き 成人 期 まで の 総合 的 な 考察
Martina Avesani1, Elettra Pomiato1, Sara Moscatelli2,3
1Paediatric Cardiology Unit, Department of Woman's and Child's Health, University Hospital of Padua, 35128 Padua, Italy.
Children (Basel, Switzerland)
|August 28, 2025
まとめ
小児および若年成人における心筋縮 (MH) は,一時的な状態から遺伝性心筋縮症 (HCM) まで多様です. 正確な診断と 個別的なケアが この複雑な状態の管理に不可欠です
科学分野:
- 心臓病科
- 小児心臓科
- 遺伝学
背景:
- 心筋縮 (MH) は小児および若年成人集団において異質に現れます.
- 遺伝性多動性心筋病 (HCM) を含む生理学的および病理学的要素に及ぶ.
- 代謝性疾患や症候群性疾患のようなフェノコピから MHを区別することは極めて重要です.
研究 の 目的:
- 若者の心筋縮の全般的な概要を提示する.
- MHの病因,診断方法,イメージング,治療戦略に重点を置く
- MHの早期認識,評価,パーソナライズされた管理を臨床医に指導する.
主な方法:
- 小児および若年成人における心筋縮に関する現在の文献のレビュー.
- エコーカルディオグラフィーや心臓磁気共鳴 (CMR) を含む診断方法に重点を置く.
- HCM Risk-Kidsモデルのような分子診断とリスク分層化ツールの導入
主要な成果:
- 新生児の過渡性多発症から 進行性遺伝性HCMまで
- エコカルジオグラフィー,CMR,遺伝子検査は診断と特徴付けの鍵です.
- リスクの階層化モデルは意思決定を助けますが,個々の評価が必要です.
結論:
- MHの正確な診断には 早期の認識と包括的な評価が不可欠です
- 多科目のケアと パーソナライズされた治療戦略により 結果が改善されます
- 年齢に特有の症状や病因を理解することは 効果的な治療に不可欠です
関連する概念動画
Cardiomyopathy III: Hypertrophic Cardiomyopathy
45
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
45
Heart Failure II: Pathophysiology
37
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
37
Cardiomyopathy V: Interprofessional Care
32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
Pathophysiology of Cardiac Performance
799
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
799
Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Cardiomyopathy II: Dilated Cardiomyopathy
21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21


